Key Highlights

  • Vectus Biosystems shares were trading at $0.055 during the 13 November 2026 session, up 10.00%.
  • The FDA granted the company's request for a pre-IND Type B meeting on its VB0004 program in idiopathic pulmonary fibrosis.
  • Written responses from the FDA are expected by mid-November 2026.

During the Trading session on 13 November 2026, Vectus Biosystems Ltd (ASX:VBS) shares were trading at $0.055, up 10.00%, while the S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT. Vectus is developing VB0004, an oral vasoactive intestinal peptide-mimetic and natriuretic peptide receptor C-agonist for idiopathic pulmonary fibrosis. Its latest update was its quarterly activities report and Appendix 4C for the period ended 30 September 2026, released on 29 October 2026.

FDA pre-IND meeting request granted

During the quarter, the US Food and Drug Administration granted Vectus's request for a pre-Investigational New Drug Type B meeting on the proposed development program for VB0004. The interaction will take the form of written responses from the FDA, which the company expects to receive by mid-November 2026. The company said the responses will provide formal guidance on the proposed program and help inform the next stages of clinical and regulatory development.

Regulatory agent appointed in the United States

Vectus has appointed Cardinal Health Regulatory Services as its US Regulatory Agent. The agent is responsible for preparing and facilitating FDA-facing communications, interactions and submissions. Vectus and the agent have begun finalising the meeting package for submission to the FDA.

Clinical background of VB0004

Vectus said it has completed a Phase Ia clinical study of VB0004 in healthy volunteers, which established a favourable safety and pharmacokinetic profile. The company described the pre-IND interaction as an important step in its US regulatory pathway for the lead compound.

Sector context

Idiopathic pulmonary fibrosis is a chronic lung disease with limited treatment options, and drug developers in the area typically focus on slowing disease progression. Development programs in this field follow a path through pre-IND discussions, Phase I and Phase II studies, and regulatory submissions, which can take several years. Small biotechnology companies often depend on regulatory feedback and Partnership discussions to fund later-stage work.

Risks investors are watching

FDA feedback is not yet in hand, and the written responses may point to additional studies or changes to the proposed program. Clinical development is expensive and carries a high risk of delay or failure. The company's Phase Ia results were conducted in healthy volunteers, so efficacy in patients with pulmonary fibrosis remains to be shown. Vectus will also need funding to progress through later clinical stages.

What to watch ahead

The most immediate item is the FDA's written response, which is expected by mid-November. Investors will look for the company's description of the feedback, the next clinical and regulatory steps and any funding updates. The company's next Quarterly Report will also provide an update on the program.

Final Word

Vectus's latest update centres on a regulatory interaction with the FDA for VB0004. The written responses expected in the coming weeks will set out the path for the program's next stages.